AI-generated summary
The authors report a 2-site, double-blind, sham-controlled trial of low-dose transcranial near-infrared light therapy added to usual care for major depressive disorder, given twice weekly for 6 weeks. Among 49 analyzed participants, depression scores did not differ significantly between active treatment and sham. The authors conclude that this low-dose regimen was not efficacious.
- Participants
- 49
- Who or what was studied
- Adults diagnosed with major depressive disorder per DSM-IV criteria (71% female, mean age 40.8 years)
- Wavelengths
- 830 nm
- Limits stated in the abstract
- The abstract does not describe a control for sample size or power, and the sham response was low, with only 18 nonresponders re-randomized in phase 2.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on psychiatrist.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 830 nm
- Energy density (fluence)
- 65.8 J/cm2
- Power density (irradiance)
- 54.8 mW/cm2
- Power
- 2 W
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Sham, Transcranial photobiomodulation, Near-infrared, Irradiance, Depression, Dose, Transcranial magnetic stimulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.